WaveMan
WaveMan · Company
ACON · Aclarion, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ACON Aclarion (ACON) Insider Trading, Ownership & Congress Trades

Healthcare Services · Services-medical laboratories · CIK 0001635077
Quote by TradingView
Cluster · 7 insidersC-suite buying · 2
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
10
13F, latest reported quarter

What the filings say about ACON

Insiders, 180 days
+$176.6K net bought
7 buyers

Aclarion insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Aclarion, Inc. insiders bought a net $176.6K of stock across 21 Form 4 purchases and sales, with 7 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Williams Amanda M
Director
BUY
2026-08-19 SECtraded 2026-08-17
5,857
$16.0K
-28.3%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 22.7% of the 25,857 shares held after it.
  • 5 other insiders bought within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Williams Amanda M bought about $16.0K of ACON on Aug 17, 2026; 5 other insiders bought within 30 days and 10 funds added in the latest 13F quarter.
Gould Gregory A
CFO
BUY
2026-08-18 SECtraded 2026-08-14
10,000
$24.5K
-30.3%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 16.7% of the 60,000 shares held after it.
  • 5 other insiders bought within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO Gould Gregory A bought about $24.5K of ACON on Aug 14, 2026; 5 other insiders bought within 30 days and 10 funds added in the latest 13F quarter.
Bond Ryan
Director
BUY
2026-08-17 SECtraded 2026-08-13
21,122
$50.1K
-25.8%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Apr 22, 2022.
  • The trade is 27.7% of the 76,122 shares held after it.
  • 5 other insiders bought within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Bond Ryan bought about $50.1K of ACON on Aug 13, 2026, the largest insider purchase at the company since 2022; 5 other insiders bought within 30 days and 10 funds added in the latest 13F quarter.
Wesemann William
Director
BUY
2026-08-17 SECtraded 2026-08-13
2,150
$5.0K
-25.8%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on May 6, 2026.
  • -48.3% median (-48.3% mean) 90-day return after 2 previous buys.
  • The trade is 9.1% of the 23,713 shares held after it.
  • 5 other insiders bought within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Wesemann William bought about $5.0K of ACON on Aug 13, 2026; 5 other insiders bought within 30 days and 10 funds added in the latest 13F quarter.
Neal David K
Director
BUY
2026-08-17 SECtraded 2026-08-13
7,500
$18.0K
-25.8%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on May 11, 2026.
  • -46.5% median (-46.5% mean) 90-day return after 2 previous buys.
  • The trade is 25.0% of the 30,002 shares held after it.
  • 5 other insiders bought within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Neal David K bought about $18.0K of ACON on Aug 13, 2026; 5 other insiders bought within 30 days and 10 funds added in the latest 13F quarter.
21 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 16 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$176.6K over 180 days
+$125.7K over 90 days
more than 83% of Healthcare Services
Congress
no House purchase disclosed in the last 12 months
Funds
10 funds bought in last quarter
below 94% of Healthcare Services
Revenue
+65.6% year over year
more than 92% of Healthcare Services
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
1.9% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 68% of Healthcare Services
The situation: each line is one rule over one dataset
7 insiders independently bought a net $176.6K while the stock fell 43% over six months, with no planned sales queued.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ACON

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-74.2%12M
-75%-47%-19%+9%2025-102025-122026-022026-042026-062026-082026-10 2026-08-13 · Bond Ryan bought $50.1K2026-08-14 · Gould Gregory A bought $24.5K2026-05-11 · Ness Brent bought $20.0K2026-05-12 · Breidbart Scott bought $18.0K2026-08-13 · Neal David K bought $18.0K2026-08-17 · Williams Amanda M bought $16.0K2026-08-13 · Ness Brent bought $12.1K2026-05-11 · Neal David K bought $7.8K2026-05-06 · Wesemann William bought $5.2K2026-08-13 · Wesemann William bought $5.0K2025-11-26 · Ness Brent bought $62
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ACON: institutional holders (13F)

13F holdings, latest reported quarter
BRIDGEWAY CAPITAL MANAGEMENT, LLC
19,480 sh
$56.1K
CAPTRUST FINANCIAL ADVISORS
95,459 sh
$50.8K
VANGUARD FIDUCIARY TRUST CO
16,028 sh
$46.2K
SUSQUEHANNA INTERNATIONAL GROUP, LLP
15,355 sh
$44.2K
GEODE CAPITAL MANAGEMENT, LLC
12,128 sh
$34.9K

Congress trades in ACON

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ACON planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

ACON mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Fund
$56.1K position · as of 2026-06-30
0.1%
Fidelity Extended Market Index Fund
$72.0K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$19.5K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$1.6K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
7 insiders reported buying shares.
The record shows a net $176.6K bought by insiders over 180 days, 10 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
NTRACSTLPGNYHIMSWGSPRVATDOCAVAHGHADUSSERABDSX

ACON financials

Revenue growth
+65.6%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$83.8K
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-59.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-56.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-62.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$75.7K$45.7K$75.4K$60.4K
Gross profit$6.8K-$38.9K-$324-$4.9K
Operating income-$7.1M-$5.5M-$4.9M-$5.6M
Net income-$7.2M-$7.0M-$4.9M-$7.1M
EPS (diluted)-13.61-7,478.90-79,782.00-19.61
Operating cash flow-$7.2M-$5.3M-$3.6M-$4.9M
Cash$12.0M$453.7K$1.0M$1.5M
SEC XBRL, fiscal years, as known on 2026-10-27

ACON Stock Sonar score 5/7 axes

Find similar shapesCompare

ACON ranks highest on growth (92nd percentile) and insider conviction (91st), and lowest on institutional and government (6th), among Healthcare Services peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
15
Inputs
  • Return on equity-59.0% · 22 pct, sector of 70
  • Return on assets-56.1% · 17 pct, sector of 88
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-62.3% · 7 pct, sector of 68
Growth
92
Inputs
  • Revenue growth, YoY+65.6% · 92 pct, sector of 87
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
91
Inputs
  • Net Form 4 buying (codes P and S), 180d$177K · 83 pct, sector of 64
  • Insider buyers, 180d7 · 100 pct, sector of 64
Institutional and government
6
Inputs
  • Funds adding, latest quarter10 · 6 pct, sector of 73
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
84
Inputs
  • Short interest, % of float+1.9% · 73 pct, sector of 95
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+2.3% · 94 pct, sector of 72
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ACON filings, in plain words

Are Aclarion insiders buying or selling ACON?

In the 180 days to 2026-10-27, Aclarion insiders were net buyers, a net $176.6K across purchases and sales reported on Form 4, by 7 buyers.

Read the full summary

In the 180 days to 2026-10-27, Aclarion insiders were net buyers of ACON, a net $176.6K across purchases and sales reported on Form 4 by 7 buyers. 6 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies